MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Vanda strongly disputes the FDA’s reasoning
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Subscribe To Our Newsletter & Stay Updated